An observational study in Type1 Diabetes Mellitus and Type 2 Diabetes Mellitus, sponsored by Joslin Diabetes Center. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Joslin Diabetes Center · Observational
The purpose of this study is to evaluate the accuracy and efficacy of the Cambridge Medical Technologies, LLC LabPatch Continuous Glucose Monitoring (CGM) System compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite.
The LabPatch system includes:
Study design:
This is a cross-sectional, pilot, precision, single center, single-arm study, enrolling 30 adult subjects with type 1 or type 2 diabetes treated with insulin.
The study will include both a screening visit and a single study visit.The accuracy of the LabPatch CGM will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
Screening Visit:
Following the informed consent process, screening evaluation will determine subject eligibility for enrollment, including:
Study Visit (visit window: screening visit + 0 to 30 Days):
Subject Admission
The subject will arrive at the clinical research center at Joslin Diabetes Center during the day, no later than 10:00 AM and the following will be performed:
During this visit the following procedures will be conducted:
Before discharge:
Subject Instructions prior to the visit
Estimated Visit Duration
Adult subjects with type 1 or type 2 diabetes treated with insulin.
Exclusion Criteria:
30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
Device: LabPatch Continuous Glucose Monitoring (CGM)
1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides. 2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618"\] x 15.7 mm \[0.618"\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact. 3. A wire that connects the chip to a laptop that continuously captures glucose data.
Mean absolute relative difference (MARD)
Blood glucose values (mg/dL) from the LabPatch system and reference YSI, One Touch Verio, and FreeStyle Lite will be used to report the mean absolute relative difference (MARD) in Percentage (%).
Time frame: Baseline, every 15 minutes after breakfast for 2 hours, every 30 minutes until lunch time, and every 30 minutes after lunch for 2 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joslin Diabetes Center